வைராலஜி சிகிச்சை பரப்பளவு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வைராலஜி சிகிச்சை பரப்பளவு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வைராலஜி சிகிச்சை பரப்பளவு Today - Breaking & Trending Today

Gilead's Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI

March 09, 2021
–
–
Late-Breaking Preclinical Data Support Further Study of Lenacapavir as a Long-Acting Agent for HIV Prevention –
FOSTER CITY, Calif. (BUSINESS WIRE)
Gilead Sciences, Inc. (Nasdaq: GILD) today presented additional results from the Phase 2/3 CAPELLA trial evaluating the company’s investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, in heavily treatment-experienced people with multi-drug resistant HIV-1 infection. The data build on the positive primary endpoint results announced previously. The new interim efficacy results demonstrate that lenacapavir administered subcutaneously every six months maintained high rates of virologic suppression through 26 weeks in a difficult-to-treat patient population with limited therapy options and high unmet medical need. In this analysis of the ongoing maintenance period of CAPELLA, which evaluated lenacapavir in combination with an optimized background regimen, 73% (n 19/26) of part ....

United States , Foster City , Jacquie Ross , Brian Plummer , Jamesj Rahal Jr , Diana Brainard , Sorana Segal Maurer , Exchange Commission , Gilead Sciences , Gilead On Twitter Sciences , Gilead Public Affairs , Division Of Infectious Diseases At Newyork , Gilead Sciences Inc , Lenacapavir Maintained High Rates , Multi Drug Resistant , Long Acting Agent , Senior Vice President , Virology Therapeutic Area , Breakthrough Therapy Designation , Infectious Diseases , Newyork Presbyterian Queens , Site Principal Investigator , North America , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , வளர்ப்பு நகரம் ,

Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI

Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI
98% of Treatment-Naïve Patients Achieved and Maintained Undetectable Viral Load with Biktarvy Through Four Years in the Open-Label Extension Phase of Two Phase 3 Studies – – Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks – Gilead Sciences, Inc. today announced new, …
– Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks – ....

United States , Foster City , Jacquie Ross , Brian Plummer , Kimberly Workowski , Diana Brainard , Exchange Commission , Gilead Sciences , Emory University , Gilead On Twitter Sciences , Gilead Public Affairs , Gilead Sciences Inc , Patients Achieved , Maintained Undetectable Viral Load , Biktarvy Through Four Years , Open Label Extension Phase , Two Phase , Adults Reached , Certain Transmitted Drug Resistance , Opportunistic Infections , Senior Vice President , Virology Therapeutic Area , Important Safety Information , Safety Information , Drug Interactions , Antiretroviral Pregnancy Registry ,

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone's Vaccine Platform Technology for HIV Cure

Press release content from Business Wire. The AP news staff was not involved in its creation.
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
February 1, 2021 GMT
FOSTER CITY, Calif. & EMERYVILLE, Calif. (BUSINESS WIRE) Feb 1, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection. ....

United States , Foster City , Andrew Allen , Jacquie Ross , Dan Budwick , Karin Jooss , Alexandra Santos , Diana Brainard , Mark Snyder , Gilead Sciences , National Institutes Of Health , Gritstone Oncology Inc , Melinda Gates Foundation , Gilead Sciences Inc , Exchange Commission , Jolla Institute For Immunology , Gritstone Oncology , Senior Vice President , Virology Therapeutic Area , Chief Executive Officer , Executive Vice President , Chief Scientific Officer , National Institutes , Quarterly Report , Private Securities Litigation Reform Act , Gilead Contacts ,